Author

Brendon Binneman

Observed names: B Brendon, B. Binneman, BRENDON BINNEMAN, Binneman, B, Binneman, Brendon

Observed institution: Pfizer (United States)

OpenAlex ID: A5044619294

A 6-Week Randomized, Placebo-Controlled Trial of CP-316,311 (a Selective CRH 1 Antagonist) in the Treatment of Major Depression

2008 · Brendon Binneman, Douglas Feltner, et al. · American Journal of Psychiatry · 253

Longitudinal study of symptoms and cognitive function in chronic schizophrenia

2002 · Catherine Hughes, Veena Kumari, et al. · Schizophrenia Research · 214

Ponezumab in mild‐to‐moderate Alzheimer's disease: Randomized phase II PET‐PIB study

2017 · Jaren W. Landen, Niels Andreasen, et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 69

PDF

Multiple‐dose ponezumab for mild‐to‐moderate Alzheimer's disease: Safety and efficacy

2017 · Jaren W. Landen, Sharon Cohen, et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 64

PDF

A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer’s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil

2018 · Terence Fullerton, Brendon Binneman, et al. · Alzheimer s Research & Therapy · 32

PDF

A Modest Increase in 11C-PK11195-Positron Emission Tomography TSPO Binding in Depression Is Not Associated With Serum C-Reactive Protein or Body Mass Index

2021 · Julia J. Schubert, Mattia Veronese, et al. · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · 31

PDF

An 8-Week, Randomized, Phase 2, Double-Blind, Sequential Parallel-Group Comparison Study of Two Dose Levels of the GABAA Positive Allosteric Modulator PF-06372865 Compared With Placebo as an Adjunctive Treatment in Outpatients With Inadequate Response to Standard of Care for Generalized Anxiety Disorder

2018 · Arthur Simen, Mark Whitlock, et al. · Journal of Clinical Psychopharmacology · 26

Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer’s disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study

2013 · Izuru Miyoshi, Yoko Fujimoto, et al. · International Journal of Clinical Pharmacology and Therapeutics · 26

Neurological Soft Signs and Their Relationship to Cognitive and Clinical Efficacy of Atypical Antipsychotics in Schizophrenia

2004 · M. Das, V. Kumari, et al. · Schizophrenia Bulletin · 26

PDF

P1‐012: Effect of ponezumab on CSF biomarkers: Pooled analysis of phase IIa studies in subjects with mild‐to‐moderate Alzheimer's disease

2012 · Carol Cronenberger, Pam Schwartz, et al. · Alzheimer s & Dementia · 24

PDF

Pharmacological modulation of TSPO in microglia/macrophages and neurons in a chronic neurodegenerative model of prion disease

2023 · Marta Vicente-Rodríguez, Renzo Mancuso, et al. · Journal of Neuroinflammation · 17

PDF

P.3.c.073 Effects of asenapine on cognitive function in acute schizophrenia: a placebo- and risperidone-controlled trial

2007 · K. Fleming, S.G. Potkin, et al. · European Neuropsychopharmacology · 14

Cerebral Metabolic Effects of Intravenous Glycine in Healthy Human Subjects

2006 · Alexander Neumeister, Richard Carson, et al. · Journal of Clinical Psychopharmacology · 14

P4‐209: Safety, tolerability, pharmacokinetics and pharmacodynamics of monthly and quarterly doses of Ponezumab (PF‐04360365) in subjects with mild‐to‐moderate Alzheimer's disease

2012 · Jaren Landen, Niels Andreasen, et al. · Alzheimer s & Dementia · 4

Cognitive effects of clozapine and olanzapine in patients with chronic schizophrenia

2002 · Tarang Sharma, Veena Kumari, et al. · Research Portal (King's College London) · 3

Evaluation of the use of the Scale for the Assessment and Rating of Ataxia (SARA) in healthy volunteers and patients with schizophrenia

2018 · Nina Shaafi Kabiri, Sana Syed, et al. · Journal of the Neurological Sciences · 1

P1‐047: A Phase 2 Clinical Trial of PF‐05212377 (SAM‐760) in Subjects with Mild to Moderate Alzheimer's Disease with Existing Neuropsychiatric Symptoms on a Stable Daily Dose of Donepezil

2016 · Terence Fullerton, Brendon Binneman, et al. · Alzheimer s & Dementia · 1

Commentary: Wayne Fenton's Impact on Industry

2007 · A. Breier, L. Alphs, et al. · Schizophrenia Bulletin · 1

Change in negative symptoms with risperidone predicts improved quality of life in schizophrenia

2000 · W. Soni, R. Mehrotra, et al. · Schizophrenia Research · 1

Neurological soft signs in chronic schizophrenia: Clinical, cognitive and structural correlates

2000 · R. Mehrotra, W. Soni, et al. · Schizophrenia Research · 1

Audio Recording for Independent Confirmation of Clinical Assessments in Generalized Anxiety Disorder.

2018 · Steven D Targum, Christopher Murphy, et al. · PubMed

Comments on "Presidential Address: Advocacy as Leadership"

2007 · CATHRYN CLARY, ANTONY LOEBEL, et al. · American Journal of Psychiatry

Independence of neuropsychological functioning from symptom improvement in chronic schizophrenia

2001 · Hughes, C, Kumari, V, et al. · Research Portal (King's College London)

The functional neuroanatomy of schizophrenic syndromes: An investigation of brain function during cognitive processing

2000 · G.D. Honey, E.T. Bullmore, et al. · Schizophrenia Research

Role of neurological soft signs in determining responsiveness to atypical antipsychotic medication in schizophrenia

2000 · Mrigendra Das, W. Soni, et al. · Research Portal (King's College London)

Works count: 28

Citation count: 822

H-index: 13

I10-index: 13